Anti-inflammatory effects of resveratrol occur via inhibition of lipopolysaccharide-induced NF-κB activation in Caco-2 and SW480 human colon cancer cells

Br J Nutr. 2012 Nov 14;108(9):1623-32. doi: 10.1017/S0007114511007227. Epub 2012 Jan 17.

Abstract

Resveratrol, a polyphenol abundantly found in grapes and red wine, exhibits beneficial health effects due to its anti-inflammatory properties. In the present study, we evaluated the effect of resveratrol on inflammatory responses induced by lipopolysaccharide (LPS) treatment of human intestinal Caco-2 and SW480 cell lines. In the LPS-treated intestinal cells, resveratrol dose-dependently inhibited the expression of inducible NO synthase (iNOS) mRNA as well as protein expression, resulting in a decreased production of NO. In addition, Toll-like receptor-4 expression was significantly diminished in LPS-stimulated cells after resveratrol pre-treatment. To investigate the mechanisms by which resveratrol reduces NO production and iNOS expression, we examined the activation of inhibitor of κB (IκB) in LPS-stimulated intestinal cells. Results demonstrated that resveratrol inhibited the phosphorylation, as well as the degradation, of the IκB complex. Overall, these results show that resveratrol is able to reduce LPS-induced inflammatory responses by intestinal cells, interfering with the activation of NF-κB-dependent molecular mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / metabolism*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Agents, Phytogenic / metabolism*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Caco-2 Cells
  • Cell Line, Tumor
  • Cell Survival
  • Colonic Neoplasms / immunology
  • Colonic Neoplasms / metabolism*
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / prevention & control
  • Dietary Supplements / adverse effects
  • Down-Regulation
  • Enterocytes / cytology
  • Enterocytes / immunology
  • Enterocytes / metabolism*
  • Enterocytes / pathology
  • Humans
  • I-kappa B Proteins / metabolism
  • Inflammatory Bowel Diseases / diet therapy
  • Inflammatory Bowel Diseases / immunology
  • Inflammatory Bowel Diseases / metabolism*
  • Inflammatory Bowel Diseases / pathology
  • Lipopolysaccharides
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / genetics
  • Nitric Oxide Synthase Type II / metabolism
  • Phosphorylation
  • Protein Processing, Post-Translational
  • Proteolysis
  • RNA, Messenger / metabolism
  • Resveratrol
  • Stilbenes / adverse effects
  • Stilbenes / metabolism*
  • Stilbenes / therapeutic use
  • Toll-Like Receptor 4 / genetics
  • Toll-Like Receptor 4 / metabolism

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents, Phytogenic
  • I-kappa B Proteins
  • Lipopolysaccharides
  • NF-kappa B
  • RNA, Messenger
  • Stilbenes
  • TLR4 protein, human
  • Toll-Like Receptor 4
  • Nitric Oxide
  • NOS2 protein, human
  • Nitric Oxide Synthase Type II
  • Resveratrol